Does PTCY increase the risk of infections?

PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in matched donors allowed better evaluation of infectious risk conferred separately by PTCY or donor type. PTCY increased the risk of bacterial infections, both in haploidentical and matched donors, mainly pre-engraftmen...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2023-11, Vol.62, p.101092-101092, Article 101092
Main Authors: Mikulska, Malgorzata, Bartalucci, Claudia, Raiola, Anna Maria, Oltolini, Chiara
Format: Article
Language:English
Subjects:
Bacterial Infections
BK virus
Bloodstream infections
Cyclophosphamide
Cyclophosphamide - therapeutic use
Cytomegalovirus
Fungal infections
Graft vs Host Disease - prevention & control
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Multidrug resistant bacteria
Prospective Studies
Unrelated Donors
Virus Diseases - complications
Virus Diseases - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in matched donors allowed better evaluation of infectious risk conferred separately by PTCY or donor type. PTCY increased the risk of bacterial infections, both in haploidentical and matched donors, mainly pre-engraftment bacteremias. Bacterial infections, particularly due to multidrug-resistant Gram-negatives, were main causes of infection-related deaths. Higher rates of CMV and other viral infections were reported, mainly in haploHSCT. The role of donor might be more important than the role of PTCY. PTCY increased the risk of BK virus associated hemorrhagic cystitis, and seemed associated with higher risk of respiratory viral infections. Fungal infections were frequent in haploHSCT PCTY cohorts without mold active prophylaxis, but the exact role of PTCY needs to be established. Infections appear to be increased in patients receiving PTCY, although the exact role of GvHD prophylaxis and donor type can only be assessed in prospective trials.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2023.101092